がん分子標的薬剤に耐性を獲得したがん細胞の生物学的特性に関する研究 by Iwai Toshiki & 岩井 俊樹
Studies on Biological Characteristics of
Cancer Cells after Acquiring Resistance to
Molecular-Targeted Therapy
著者 Iwai Toshiki
year 2018
その他のタイトル がん分子標的薬剤に耐性を獲得したがん細胞の生物
学的特性に関する研究
学位授与大学 筑波大学 (University of Tsukuba)
学位授与年度 2017
報告番号 12102甲第8564号
URL http://doi.org/10.15068/00152264
  
 
 
 
 
Studies on Biological Characteristics of Cancer Cells 
after Acquiring Resistance to Molecular-Targeted 
Therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 January 2018 
 
 
 
 
 
Toshiki IWAI 
 
 
 
 
 
  
 
 
 
 
Studies on Biological Characteristics of Cancer Cells 
after Acquiring Resistance to Molecular-Targeted 
Therapy 
 
 
 
 
 
 
 
 
 
 
A Dissertation Submitted to 
the Graduate School of Life and Environmental Sciences, 
 the University of Tsukuba 
in Partial Fulfillment of the Requirements 
for the Degree of Doctor of Philosophy in Biological Science 
 ( Doctoral Program in Biological Sciences ) 
 
 
 
Toshiki IWAI 
 
 
 
 
 
  
 
 
Contents 
 
 
 
Abstract 
General introduction 
 
 
Chapter I. Biological characters of cancer cells after acquiring resistance to 
anti-VEGF antibody 
 
Introduction 
Materials and methods 
Results 
Discussion 
 
 
Chapter II. Biological characters of cancer cells after acquiring resistance to 
EGFR-TKI 
 
Introduction 
Materials and methods 
Results 
Discussion 
 
 
General Discussion 
Acknowledgements 
References 
Table 
Figures 
1 
 
Abstract 
Vascular endothelial growth factor (VEGF)-neutralizing antibody and an epidermal 
growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) have become increasingly 
important for treating cancer. However, almost all patients develop progressive disease 
(PD) during the therapy.  
It was demonstrated that second-line chemotherapy together with anti-VEGF 
antibody after PD on first-line therapy including anti-VEGF antibody showed clinical 
benefits. In my study, to investigate the mechanisms underlying the effect of continued 
administration of anti-VEGF antibody plus capecitabine even after resistance to 
anti-VEGF antibody was acquired, I established the anti-VEGF antibody PD model 
using HT-29 cancer cell. The combination therapy exhibited significantly stronger 
antitumor and anti-angiogenic activities than did each monotherapy in PD model. 
Capecitabine treatment increased the intratumoral VEGF level compared with the 
control group; however, the combination with anti-VEGF antibody neutralized VEGF. 
Among angiogenic factors other than VEGF, intratumoral galectin-3, which reportedly 
promotes angiogenesis both dependent on and independently of VEGF, was decreased 
in the capecitabine group and the combination group compared with the control group. 
These results suggested that capecitabine has a dual mode of action: namely, inhibition 
of tumor cell growth and inhibition of galectin-3 production by tumor cells. 
Next, to demonstrate the clinical relevance of EGFR-TKI treatment after PD, I 
investigated whether continuous administration of an EGFR-TKI in combination with 
chemotherapy has a useful effect on PD development during EGFR-TKI treatment. For 
this purpose, I examined the antitumor effect of combination therapy in 
EGFR-TKI-resistant tumor xenograft models: EBC-1, H1975, HCC827TR3, and HPAC. 
As a result, the combination therapy showed a significantly higher antitumor activity 
compared with chemotherapy alone in all xenograft models except H1975. Furthermore, 
EGFR-TKI alone suppressed the EGFR phosphorylation in HPAC tumors and the two 
NSCLC cell lines other than H1975. Therefore, when an EGFR-TKI continues to inhibit 
EGFR phosphorylation, combination therapy with an EGFR-TKI can be considered 
effective, even in EGFR-TKI-resistant tumor xenograft models. 
In these studies, I demonstrated that tumors continue to express the target molecule 
after acquiring resistance to therapy, and combining targeted therapy with chemotherapy 
exerted strong antitumor activity, even after resistance to the targeted therapy was 
acquired. I thus suggest the clinical relevance of using targeted therapy in a combination 
therapy beyond PD. 
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General Introduction 
Cancer is a deadly disease in which abnormal cells grow without control, metastasize 
to other organs, and ultimately cause organ failure by invading the surrounding tissues. 
With the number of cancer patients increasing every year, the question of how to treat 
cancer is one of the major issues still to be resolved in modern medicine. Although 
surgery, radiation therapy, and drug therapy comprise the treatment options available for 
cancer patients, in the metastasis phase the only treatment option is drug therapy. To 
improve the efficacy of drug therapy, a variety of targeted therapies have been 
developed focusing on several proteins that are genetically overexpressed on the surface 
or activated in the cytoplasm of cancer cells, such as c-KIT receptor, and mTOR, and 
the epidermal growth factor receptor (EGFR) family (1-3).  
EGF was discovered 30 years ago and its role in cell growth has been elucidated. 
EGFR is a transmembrane glycoprotein with an extracellular EGF-binding domain and 
an intracellular domain possessing intrinsic tyrosine kinase activity (4-6). Binding by 
the EGF ligand activates the receptor's tyrosine kinase, initiating cascades of 
intracellular signaling. EGFR is the major contributor in a complex signaling cascade 
that modulates growth, signaling, differentiation, adhesion, migration, and survival of 
cancer cells. High levels of EGFR expression have been reported in a wide range of 
human malignancies (7-9), and members of the EGFR family are among the most often 
targeted proteins. EGFR-tyrosine kinase inhibitor (EGFR-TKI) reversibly binds to the 
intracellular domain of EGFR. This blocks autophosphorylation of EGFR with 
subsequent inhibition of the downstream signaling pathways which promote cell 
proliferation. Clinical results have demonstrated that EGFR-TKI monotherapy or 
combination therapy with chemotherapy showed a survival benefit for patients with 
NSCLC or pancreatic cancer, respectively (10, 11). However, most of these patients 
developed progressive disease (PD) during such therapies. 
Mechanisms of acquired resistance to EGFR-TKI, which result in continued 
signaling in the presence of EGFR-TKI, can be classified into two broad categories: 
resistant EGFR mutations, and activation of bypass pathways or downstream pathways 
(12). In the former case, an EGFR mutation restores the binding pocket’s affinity for 
adenosine triphosphate, rendering the competitive inhibition of adenosine triphosphate 
by TKI ineffective (13). The high rate of T790M resistance after first- and 
second-generation TKI therapy has prompted the development of third-generation 
EGFR-TKI. In the latter case, the signaling that was inhibited by EGFR-TKI therapy is 
restored by bypass pathways activated through compensative utilization of other related 
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receptors or circumvention of the EGFR, or both. For example, MET amplification that 
results in high-level Met receptor expression can enhance heterodimerization with 
HER3 (ErbB3) to activate downstream PI3K signaling despite inhibition of EGFR 
activation (14). As with MET, HER2 (ErbB2) amplification leads to parallel signaling 
that bypasses the effects of EGFR-TKI (15). Upregulation of insulin-like growth factor 
1 receptor has also been shown to confer resistance to EGFR-TKI (16, 17). However, 
blockades of these receptors have not been effective in clinical trials (18). 
In another approach, therapy has been developed to target not the tumor cells but the 
tumor stromal cells. Angiogenesis is one of the fundamental causes of tumor 
progression (19). Folkman has suggested that tumor growth is angiogenesis-dependent 
and proposed that anti-angiogenesis might be an effective therapeutic strategy to treat 
cancer (20, 21). As tumor blood vessels are mainly made from endothelial cells, an 
important factor in tumor angiogenesis and growth is vascular endothelial growth factor 
(VEGF) (22-25). VEGF is a heparin binding growth factor, and is a dimeric protein 
composed of two identical subunits (26). Six subtypes of VEGF, VEGF-A, -B, -C, -D, 
-E, and -F (27-31) and three receptors, VEGFR-1, -2, and -3 (32, 33), are known. Each 
VEGF subtype binds to multiple VEGFR. Activation of VEGFR-1 results in 
angiogenesis and migration of hematopoietic cells, that of VEGFR-2 in angiogenesis 
and increased permeability (34), and that of VEGFR-3 in lymphatic formation (35). 
It has been reported that VEGF is overexpressed in most human tumors (23, 36), 
which results in disorganization of the tumor microvasculature and lack of the 
conventional hierarchy of blood vessels, making arterioles, capillaries, and venules 
unidentifiable (37-40). In the clinical setting, anti-angiogenic therapy targeting VEGF 
has been demonstrated to be effective for several kinds of cancers, including colorectal 
cancer (41-43). 
Because endothelial cells are genetically stable, it is generally considered that 
refractoriness to combination therapy with chemotherapeutic agents plus anti-VEGF 
antibody is mostly caused by resistance to the chemotherapeutic agents rather than to 
anti-VEGF antibody (44, 45). In this context, second-line therapies including 
anti-VEGF antibody (bevacizumab beyond progression therapy; BBP therapy) were 
intensively studied and were found to demonstrate clinical benefits in patients with 
metastatic colorectal and breast cancer (46, 47). However, VEGF-independent 
angiogenesis has been reported as a mechanism of resistance to anti-VEGF therapy (48). 
Therefore, resistance to anti-VEGF antibody cannot be excluded as a mechanism of 
resistance to combination therapy with chemotherapeutic agents plus anti-VEGF 
antibody. 
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In Chapter I of this study, I hypothesized that BBP therapy is effective even after a 
tumor acquires resistance to anti-VEGF antibody, and I investigated the effective 
mechanism of BBP therapy. I used a xenograft model of a human colon cancer cell line 
with acquired resistance to anti-VEGF antibody to investigate the antitumor effect of 
the combination of chemotherapy plus anti-VEGF antibody and its mechanism of action 
in terms of angiogenic factors produced by stromal cells and tumor cells. 
In Chapter II of this study, I analyzed the characteristics of EGFR-TKI-resistant 
tumor cells and investigated the antitumor activity of combination therapies of 
EGFR-TKI with various cytotoxic chemotherapies, using not only an in vivo 
EGFR-TKI PD xenograft model but also EGFR-TKI-resistant tumor cell xenografts, to 
show the clinical relevance of continuing EGFR-TKI treatment after development of 
PD. 
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Chapter I. 
 
 
Biological characters of cancer cells after acquiring 
resistance to anti-VEGF antibody  
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Introduction 
Bevacizumab, a humanized anti-VEGF monoclonal antibody, is usually administered 
in combination with chemotherapeutic agents. Although these combination therapies 
improve overall survival and progression-free survival in colorectal cancer patients, 
almost all responders ultimately develop disease progression (PD). Therapies including 
bevacizumab after PD (bevacizumab beyond progression therapy; BBP therapy) were 
found to demonstrate clinical benefits in patients with metastatic colorectal and breast 
cancer (46, 47).  
Capeciatbine is an oral fluoropyrimidine drug widely used. It is converted first to 
5’-deoxy-5-fluorocytidine by carboxylesterase located in the liver, then to 
5’-deoxy-5-fluouridine by cytidine deaminase expressed in the liver and various solid 
tumors, and finally to 5-FU by thymidine phosphorylase highly expressed in many 
tumors. It has been reported that capecitabine and 5-FU inhibited angiogenesis in colon 
and gastric cancer models by suppressing the secretion of angiogenic factors from tumor 
cells (49, 50). A clinical study has reported that the combination therapy of 
bevacizumab with chemotherapy involved in capecitabine improves progression free 
survival compared with chemotherapy alone in several kinds of cancers including 
colorectal cancer. And this combination was used for 26% of patients in the metastatic 
colorectal cancer BBP therapy trial and 60% of patients in the breast cancer BBP 
therapy trial (46, 47). 
In this study, I used a xenograft model of a human colon cancer cell line with 
acquired resistance to bevacizumab (hereafter, bevacizumab PD model) to investigate 
the antitumor effect of the combination of capecitabine plus bevacizumab and its 
mechanism of action in terms of angiogenic factors produced by stromal cells and tumor 
cells. 
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Materials and Methods 
Reagents 
Bevacizumab and capecitabine were provided by F. Hoffmann-La Roche (Basel, 
Switzerland) as a liquid and fine powder, respectively. Human immunoglobulin G 
(HuIgG) was purchased from MP Biomedicals (Solon, OH, USA). Capecitabine was 
dissolved in 40 mM citrate buffer (pH 6.0) containing 5% gum arabic (capecitabine 
vehicle). 
 
Cells 
Five human colorectal cancer cell lines (COLO 205, HCT-8, HCT-116, LS411N, and 
HT-29), and two mouse cancer cell lines (B16-F1 and LLC1) were used in this study. 
All cancer cell lines were purchased from American Type Culture Collection (Manassas, 
VA, USA). COLO 205 and LS411N were maintained in RPMI-1640 supplemented with 
2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4.5 g/l glucose, 1.5 g/l 
sodium bicarbonate, and 10% FBS at 37°C under 5% CO2. HCT-116 and HT-29 were 
maintained in McCoy's 5A supplemented with 10% FBS at 37°C under 5% CO2. HCT-8 
was maintained in RPMI-1640 supplemented with 1 mM sodium pyruvate and 10% 
horse serum at 37°C under 5% CO2. B16-F1 and LLC1 were maintained in D-MEM 
supplemented with 10% FBS at 37°C under 5% CO2. 
 
Animals 
Five-week-old male BALB/c-nu (CAnN.Cg-Foxn1 <nu>/CrlCrlj) mice were 
obtained from Charles River Laboratories Japan (Yokohama, Japan). All animals were 
allowed to acclimatize and recover from shipping-related stress for at least 4 days prior 
to the study. The health of the mice was monitored by daily observation. The animals 
were allowed free access to chlorinated water and irradiated food, and the animals were 
kept under a controlled light-dark cycle (12 h–12 h). All animal experiments were 
reviewed and approved by the Institutional Animal Care and Use Committee at Chugai 
Pharmaceutical Co., Ltd. 
 
In vivo tumor growth inhibition by bevacizumab 
Each mouse was inoculated subcutaneously into the right flank with 5×106 
cells/mouse of human colorectal cancer cell line (either COLO 205, HCT-8, HCT 116, 
LS411N or HT-29). Several weeks after tumor inoculation, mice were randomly 
allocated to control and treatment groups. Bevacizumab (5 mg/kg) was administered 
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intraperitoneally (i.p.) once a week for 3 weeks. To evaluate the antitumor activity of 
the test agents, tumor volume (TV) was measured twice a week. The tumor volume was 
estimated from the equation TV = ab2/2, where a, and b are tumor length and width, 
respectively. Tumor volume ratios were calculated by dividing mean tumor volume on 
day 8 by mean tumor volume on day 1 and mean tumor volume on day 22 by mean 
tumor volume on day 15 in both the bevacizumab and control groups. 
 
Combination of bevacizumab plus chemotherapy in the bevacizumab PD model 
Mice inoculated with HT-29 cells that had been treated with bevacizumab (5 mg/kg) 
on days 1 and 8 (1st treatment) were randomly allocated to control IgG plus 
capecitabine vehicle (control), bevacizumab, capecitabine, and bevacizumab plus 
capecitabine groups on day 29. Bevacizumab (5 mg/kg) was administered i.p. Once a 
week and capecitabine (359 mg/kg) was administered orally (p.o.) every day for 3 
weeks (2nd treatment). To evaluate the antitumor activity and the tolerability of the test 
agents, TV and body weight was measured twice a week. 
 
Quantification of microvessel density in tumor tissues 
HT-29 tumor tissues were resected from the bevacizumab PD model on day 50, and 
microvessel density (MVD) was evaluated immunohistochemically by using a 
monoclonal anti-mouse CD31 antibody (rat anti-mouse CD31 monoclonal antibody, 
clone MEC 13.3; BD Biosciences, Franklin Lakes, NJ, USA). Immunohistochemical 
staining was performed as described previously using 5-µm-thick sections from freshly 
frozen tissues (51). MVD (%) was calculated from the ratio of the CD31-positive 
staining area to the total observation area. Fields excluding necrotic areas were analyzed. 
Positive staining areas were calculated by using imaging analysis software (Definiens 
Tissue Studio; Definiens, Munich, Germany). 
 
Flow cytometric analysis of tumor-infiltrating cells 
HT-29 tumors were collected from xenografted mice on day 26 after inoculation. 
Single cell suspensions were prepared by mincing the tumors, followed by treating with 
a Tumor Dissociation kit for human tumor tissue (Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany) in a gentleMACS Dissociator (Miltenyi Biotec). The cells were 
stained with antibodies to mouse CD11b (PerCP/Cy5.5), Gr1 (APC), and CD45 (FITC) 
(BioLegend, San Diego, CA, USA) at 1 µg/ml and analyzed by using FACSAria 
(Becton-Dickinson) and FlowJo software (Tree Star, Ashland, OR, USA). 
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Measurement of angiogenesis-related proteins 
HT-29 tumor tissues collected on day 50 from the bevacizumab PD model were 
homogenized with cell lysis buffer (Cell Signaling Technology, Danvers, MA, USA) 
with protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA) and phosphatase 
inhibitor cocktail (Nacalai Tesque, Kyoto, Japan). The supernatant after centrifugation 
(14,000 × g, 5 min, 4°C) was used for the assays. The protein concentration of the 
supernatant was quantified using a Direct Detect spectrometer (Merck Millipore, 
Frankfurter, Germany). The relative expression profiles of human and murine 
angiogenesis-related proteins were analyzed by membrane-based antibody array 
(Proteome Profiler Angiogenesis Array kit; R&D Systems, Minneapolis, MN, USA) 
according to the manufacturer's protocol. The human angiogenesis array simultaneously 
detect the relative levels of 55 angiogenesis-related proteins (Activin A, ADAMTS-1, 
Angiogenin, Angiopoietin-1, Angiopoietin-2, Angiostatin/Plasminogen, Amphiregulin, 
Artemin, Tissue Factor/Factor III, CXCL16, DPPIV/CD26, EGF, EG-VEGF, 
Endoglin/CD105, Endostatin/Collagen XVIII, Endothelin-1, FGF acidic, FGF basic, 
FGF-4, FGF-7/KGF, GDNF, GM-CSF, HB-EGF, HGF, IGFBP-1, IGFBP-2, IGFBP-3, 
IL-1β, CXCL8/IL-8, TGF-β1, Leptin, CCL2/MCP-1, CCL3/MIP-1α, MMP-8, MMP-9, 
NRG1-β1, Pentraxin 3, PD-ECGF, PDGF-AA, PDGF-AB/PDGF-BB, Persephin, 
CXCL4/PF4, PlGF, Prolactin, Serpin B5/Maspin, Serpin E1/PAI-1, Serpin F1/PEDF, 
TIMP-1, TIMP-4, Thrombospondin-1, Thrombospondin-2, uPA, Vasohibin, VEGF, 
VEGF-C). The murine angiogenesis array simultaneously detects the relative levels of 
53 angiogenesis-related proteins (ADAMTS1, Amphiregulin, Angiogenin, 
Angiopoietin-1, Angiopoietin-3, CCL2/MCP-1, CCL3/MIP-1α, CXCL1, CXCL10, 
SDF-1, CXCL16, CXCL4, IGFBP-10, DLL4, DPPIV, EGF, Endoglin, Endostatin, FGF 
acidic, FGF basic, FGF-7/KGF, Fractalkine, GM-CSF, HB-EGF, HGF, IGFBP-1, 
IGFBP-2, IGFBP-3, IL-1α, IL-1β, IL-10, Leptin, MMP-3, MMP-8, MMP-9, IGFBP-9, 
Osteopontin, PD-ECGF, PDGF-AA, PDGF-AB/BB, Pentraxin-3, PlGF-2, Prolactin, 
Proliferin, Serpin E1/PAI-1, Serpin F1/PEDF, Thrombospondin-2, TIMP-1, TIMP-4, 
Coagulation Factor III, VEGF and VEGF-B). The array was hybridized with 280 µg of 
total protein. The concentrations of human VEGF, galectin-1, and galectin-3 were 
measured by a Quantikine ELISA kit (R&D Systems). 
 
In vitro cell treatment with 5-FU 
HT-29 cells were seeded on 24-well plates at 4×104 cells/well and were incubated 
overnight at 37°C under 5% CO2. The cells were then treated with 5-fluorouracil (5-FU) 
at 0.4, 2, or 20 µM for 24 h. 
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Statistical analysis 
The Wilcoxon test and Dunnett's test were used, with P<0.05 considered statistically 
significant. Statistical analyses were carried out using the SAS preclinical package 
(SAS Institute, Cary, NC, USA). 
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Results 
Establishing the bevacizumab PD model 
The antitumor activity of bevacizumab monotherapy was examined in five human 
colorectal cancer xenograft models in which tumors produced VEGF (Table 1). 
Bevacizumab exhibited significant antitumor activity in all of the five models when 
evaluated on day 22. To analyze in detail the mode of antitumor activity of 
bevacizumab during the treatment, tumor volume ratio was calculated separately in the 
early phase (days 1–8) and in the late phase (days 15–22). Acquisition of resistance to 
bevacizumab was evaluated by comparing the differences in tumor volume ratio in the 
early and late phases of treatment. In the COLO 205 and LS411N models, bevacizumab 
exhibited a significant antitumor activity in both the early and late phase. In the HCT-8 
and HCT 116 models, bevacizumab exhibited a significant antitumor activity only in the 
late phase. Of note, in the HT-29 model, bevacizumab exhibited significant antitumor 
activity in the early phase but not in the late phase (Fig. 1) indicating that the HT-29 
model became non-sensitive to bevacizumab during treatment. 
 
Effect of combination therapy with bevacizumab plus capecitabine on tumor 
growth and MVD in the bevacizumab PD model 
The HT-29 xenografted mice treated with bevacizumab (the bevacizumab PD model 
mice) were then treated with either control IgG plus capecitabine vehicle, bevacizumab, 
capecitabine, or bevacizumab plus capecitabine. As was expected, bevacizumab alone 
did not exhibit any significant antitumor effect, indicating that the HT-29 tumors 
pretreated with bevacizumab were refractory to bevacizumab. Capecitabine alone 
exhibited a significant antitumor effect versus control. The combination of bevacizumab 
plus capecitabine exhibited a stronger antitumor effect than capecitabine alone (Fig. 2A). 
No difference in MVD was observed in tumor tissues from the control, bevacizumab, 
and capecitabine groups. However, a significant decrease in MVD was observed in the 
combination group compared with the groups treated with each drug alone (Fig. 2B). 
 
Intratumoral stromal cell-derived angiogenic factors 
To investigate whether stromal cell-derived angiogenic factors are involved in 
sensitivity to combination therapy with bevacizumab, I examined the change in 
expression of murine angiogenesis-related factors in tumors from each treatment group. 
VEGF, bFGF, HGF, PDGF-AA, PDGF-BB, angiopoietin-1 (Ang-1), and δ-like ligand 4 
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(DLL4) were not detected. Although SDF-1 and MCP-1 were detected, none of the 
treatment groups showed any difference in these angiogenic factors (Fig. 3). 
 
Tumor cell-derived angiogenic factors 
Expression of human angiogenesis-related factors in tumors from each treatment 
group was examined by Proteome Profiler Angiogenesis Array. VEGF, bFGF, and IL-8 
were detected, whereas PDGF-AA, PDGF-BB, VEGF-C, HGF, PlGF, angiopoietin-1 
(Ang-1), and angiopoietin-2 (Ang-2) were not detected regardless of the treatment (Fig. 
4A). bFGF and IL-8 were similar in the capecitabine group, bevacizumab group, and 
combination group (Fig. 4A). VEGF level was significantly increased by capecitabine 
treatment compared with the control group, while VEGF was unsurprisingly neutralized 
by the bevacizumab-containing treatments when measured by ELISA (Fig. 4B). 
Galectin-3 levels were significantly decreased in the capecitabine and combination 
groups compared with the control group, whereas no significant difference was 
observed in galectin-1 levels (Fig. 4C). When the HT-29 cells were treated in vitro with 
5-FU, an active metabolite of capecitabine, production of galectin-3 per cell was 
inhibited in a dose-dependent manner (Fig. 4D). These data suggested that capecitabine 
inhibited galectin-3 production by HT-29 cells via a mechanism independent of cell 
growth inhibition. 
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Discussion 
In colorectal cancer, it was unclear whether maintenance with a combination of 
bevacizumab plus a chemotherapeutic agent would benefit patients who had acquired 
resistance to bevacizumab (52). In this study, it was found that the combination of 
bevacizumab plus capecitabine exhibited a strong antitumor effect on xenografted 
human colorectal cancer that had acquired resistance to bevacizumab in vivo. The 
mechanism of action of the combination of bevacizumab plus capecitabine was 
analyzed in terms of tumor angiogenesis. 
It previously was reported that the molecular targeted drugs trastuzumab exhibited 
antitumor effects when administered with chemotherapeutic agents after the tumor had 
acquired resistance to monotherapy with each if the tumor kept expressing the target 
molecules (53). If a tumor continues to express VEGF, combining bevacizumab with 
second-line chemotherapy after resistance has been acquired, may be an appropriate 
therapy. In order to establish a colorectal cancer xenograft model that develops 
resistance to bevacizumab, five human colorectal cancer xenografts which produced 
VEGF (Table 1) were treated with bevacizumab. Bevacizumab was given as the sole 
regimen to avoid development of resistance to chemotherapeutic agents. As a result, a 
bevacizumab PD model was established using the HT-29 xenograft model and was used 
in the following experiments. 
I investigated the antitumor effect of the combination of bevacizumab plus 
capecitabine by using the HT-29 PD model. Of note, the combination of bevacizumab 
plus capecitabine exhibited a significantly stronger antitumor effect than capecitabine 
alone (Fig. 2A). These data suggested that it is important to continue to inhibit VEGF 
by bevacizumab in combination with an appropriate chemotherapeutic agent even after 
the tumor has acquired resistance to bevacizumab per se. Indeed, the combination group 
showed a significant reduction in MVD, while the groups receiving bevacizumab or 
capecitabine alone did not at this stage (Fig. 2B). These results suggested that a 
synergistic anti-angiogenic effect was one of the mechanisms underlying the stronger 
antitumor effect of the combination treatment. 
To examine the mechanism through which the combination treatment exerted an 
anti-angiogenic effect in the bevacizumab PD model, I analyzed the effect of 
capecitabine on the production of several angiogenic factors by both tumor cells and 
stromal cells. Since it has been reported that the infiltration of CD11b+/Gr1+ cells into 
tumors directly or indirectly produces other angiogenic factors causing resistance to 
anti-VEGF treatment (54), I analyzed stromal cell-derived angiogenic factors and the 
14 
 
number of CD11b+/Gr1+ cells in the tumor in the HT-29 PD model. However, the 
number of CD11b+/Gr1+ cells was as few as in the anti-VEGF antibody sensitive tumor 
B16-F1 (data not shown). It has also been reported that bFGF, Ang-1, DLL4, HGF, 
SDF-1, MCP-1, PDGF-AA, and PDGF-BB from stromal cells are implicated in the 
development of resistance to VEGF inhibition (55-58). MCP-1 and SDF-1 were 
detected in the HT-29 PD model, but the levels were similar in the capecitabine, 
bevacizumab, and combination groups (Fig. 3). There were no obvious differences in 
any of the other murine angiogenic factors detected in the capecitabine, bevacizumab, or 
combination groups (Fig. 3). Therefore, the mechanism of action of the combination of 
bevacizumab plus capecitabine in this model could not be explained by the stromal 
cell-derived angiogenic factors tested. 
Next, I investigated whether tumor cell-derived angiogenic factors were involved in 
the anti-angiogenic effect of the combination therapy. I examined bFGF, IL-8, 
PDGF-AA, PDGF-BB, VEGF-C, Ang-1, Ang-2, HGF, and PlGF, which are reported to 
be angiogenic factors for tumors (59-61). PDGF-AA, PDGF-BB, VEGF-C, Ang-1, 
Ang-2, HGF, and PlGF were not detected in the HT-29 PD model. bFGF and IL-8 were 
detected but their levels were similar in the capecitabine, bevacizumab and combination 
groups (Fig. 4A). There were no obvious differences in any of the other human 
angiogenic factors detected in the capecitabine, bevacizumab, or combination groups 
(Fig. 4A). Therefore, the anti-angiogenic effect of the combination therapy in this model 
could not be explained by the factors tested. 
Recently, galectins, members of a family of carbohydrate-binding proteins with 
multiple functions, were reported to be potent prognostic marker in colorectal cancer 
and to promote angiogenesis (62, 63). Galectin-1 maintains angiogenesis in 
anti-VEGF-refractory tumors (64), and galectin-3 has been shown as an important 
mediator of VEGF- as well as FGF-mediated angiogenic response (65-67). In light of 
these findings, I investigated the intratumoral levels of human galectin-1, galectin-3, 
and VEGF in each treatment group. No significant change was observed in galectin-1 
level. However, galectin-3 level was significantly decreased in the capecitabine and 
combination groups compared with level in the control group (Fig. 4C). In addition, 
5-FU, an active metabolite of capecitabine, directly inhibited galectin-3 production by 
HT-29 cells in vitro (Fig. 4D). Since VEGF- and bFGF-mediated angiogenesis has been 
reported to be greatly reduced by galectin-3 inhibitors such as dominant negative 
galectin-3 or in galectin-3 knockdown cells in vitro and also in Gal3−/− mice (67), the 
decrease in intratumor galectin-3 level by capecitabine in my model was suggested to 
contribute, at least in part, to synergistic inhibition of angiogenesis in combination with 
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anti-VEGF antibody. Despite the reduction of galectin-3, no difference in MVD was 
observed between tumor tissues in the control and capecitabine groups. It has been 
reported that conventional 5-FU treatment may promote tumor angiogenesis by 
increasing the production of VEGF (49, 50). In contrast with galectin-3 levels, VEGF 
levels indeed increased in the capecitabine treatment group in my model (Fig. 4B). 
These bilateral effects of capecitabine on the production of angiogenic factors may be a 
reason for the apparent absence of anti-angiogenic effect by capecitabine alone. 
However, by neutralization of VEGF through concurrent administration of bevacizumab, 
a synergistic anti-angiogenic effect emerged (Fig. 4B). These data raise the possibility 
that the inhibition of galectin-3 production by capecitabine and the neutralization of 
VEGF by bevacizumab were one of the mechanisms underlying the effect of 
combination treatment. 
Regarding the development of resistance to bevacizumab in the HT-29 model, I 
investigated whether galectin-3 plays a role in acquisition of resistance. However, 
galectin-3 levels in the tumors did not change before and after developing PD (data not 
shown). Galectin-3 interacts with Mgat5-modified N-glycans on cytokine receptors 
such as EGFR, IGFR, PDGFR, and bFGFR, and activates downstream signal 
transduction pathways (68). Therefore, alteration in the expression of any of these 
receptors may cause galectin-3-induced resistance to bevacizumab. Thus, further 
investigations are required to clarify the mechanisms of resistance to bevacizumab in 
this model. 
In this study, I indicated that combination therapy with bevacizumab plus 
capecitabine could exert strong antitumor activity, even after resistance to bevacizumab 
was acquired, by recovering the anti-angiogenic effect, thus suggesting the clinical 
relevance of treatment with bevacizumab in combination therapy beyond PD.  
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Chapter II 
 
Biological characters of cancer cells after acquiring 
resistance to EGFR-TKI  
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 Introduction 
Erlotinib is an oral, small molecule tyrosine kinase inhibitor that reversibly binds to 
the intracellular domain of EGFR. This blocks autophosphorylation of EGFR with 
subsequent inhibition of the downstream signaling pathways which promote cell 
proliferation. Erlotinib is used to treat metastatic NSCLC and pancreatic cancer in many 
countries. Clinical results have demonstrated that erlotinib monotherapy or combination 
therapy with gemcitabine showed a survival benefit for NSCLC or pancreatic cancer, 
respectively (10, 11). However, most of these patients developed progressive disease 
(PD) during such therapies and it is usually considered best to switch to chemotherapy 
after developing PD. It is reported that the major mechanisms of erlotinib resistance are 
gatekeeper mutation (T790M) of EGFR and c-Met amplification in tumor cells (14, 69). 
On the other hand, it is reported that the tumor cells express active EGFR even after 
acquiring resistance to erlotinib (14, 70). Considering that EGFR overexpression is a 
factor of poor prognosis, discontinuing erlotinib treatment after PD has developed may 
be an inappropriate option and combining erlotinib with the next stage of chemotherapy 
may be an appropriate therapy. I have previously reported that the combination of 
docetaxel with erlotinib showed a synergistic effect in NSCLC cell lines in vivo 
irrespective of EGFR or K-RAS mutation status (71). 
In this study, I investigated the antitumor effect of combination therapies of erlotinib 
with various chemotherapeutic agents, docetaxel, irinotecan, and gemcitabine, using 
erlotinib-resistant tumor cell xenografts as well as an in vivo erlotinib PD xenograft 
model, to show the clinical relevance of continuing erlotinib treatment after 
development of PD. 
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Materials and Methods 
Reagents 
Erlotinib was provided by F. Hoffman-La Roche (Basel, Switzerland) as a fine 
powder and was dissolved in distilled water containing 6% (w/v) Captisol (CyDex 
Pharmaceuticals, KS, USA) and diluted with saline for in vivo experiments. Erlotinib 
was dissolved in DMSO for in vitro experiments. Docetaxel was synthesized by Kanto 
Chemical Co., Inc. (Tokyo, Japan) as a fine powder and was dissolved in saline 
containing 2.5% (v/v) polysorbate 80 (Sigma-Aldrich Co., USA) and 2.5% (v/v) ethanol 
for in vivo experiments. Irinotecan was purchased from Daiichi Sankyo Pharmaceutical 
Co., Ltd. (Tokyo, Japan) as an aqueous solution and diluted with saline. 
 
Cells 
Human non-small cell lung cancer (NSCLC) cell lines, HCC827 (exon 19 deletion 
EGFR) and H1975 (T790M mutation in EGFR), and human pancreatic cancer cell line, 
HPAC (wild-type EGFR), were obtained from the American Type Culture Collection. 
Human NSCLC cell line, EBC-1 (c-Met-amplification) was obtained from the RIKEN 
BRC (Ibaraki, Japan). Erlotinib-resistant cell line HCC827TR3 was established 
in-house by exposing HCC827 cells to increasing concentrations of erlotinib in vitro. 
The HCC827, HCC827TR3 and H1975 cells were maintained at 37°C under 5% CO2 in 
RPMI-1640 medium (Sigma-Aldrich Co.) containing 10% FBS, 10 mM HEPES, 1 mM 
sodium pyruvate, and 4.5 g/l glucose. The HPAC cell line was maintained in DMEM: 
Ham's F12 combined medium (1:1) (Invitrogen, USA) containing 5% FBS, 2 μg/ml 
insulin, 5 μg/ml transferrin, 40 ng/ml hydrocortisone, and 10 ng/ml EGF. The EBC-1 
was maintained in EMEM (Sigma-Aldrich Co.) containing 10% FBS. 
 
Animals 
Male 5-week-old BALB-nu/nu mice (CAnN.Cg-Foxn1<nu>/CrlCrlj nu/nu) were 
obtained from Charles River Japan (Kanagawa, Japan). All animals were allowed to 
acclimatize and recover from shipping-related stress for 1 week prior to the study. The 
health of the mice was monitored by daily observation. Chlorinated water and irradiated 
food were provided ad libitum, and the animals were kept in a controlled light-dark 
cycle (12 h-12 h). The protocol was reviewed by the Institutional Animal Care and Use 
Committee of Chugai Pharmaceutical Co., Ltd., and all mouse experiments were 
performed in accordance with the Guidelines for the Accommodation and Care of 
Laboratory Animals promulgated in Chugai Pharmaceutical Co., Ltd. 
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Evaluation of antitumor activity 
Study 1 
HCC827TR3, EBC-1, H1975 xenograft models and treatment. A suspension of 
tumor cells (5×106 cells/mouse) was inoculated subcutaneously into the right flank of 
mice. Tumors were allowed to reach 0.1–0.3 cm3 in size, mice were randomly allocated 
to the control group, erlotinib group, chemotherapy group and combination of erlotinib 
with chemotherapy group and these were treated with vehicle of erlotinib and vehicle of 
chemotherapy, erlotinib and vehicle of chemotherapy, vehicle of erlotinib and 
chemotherapy, or erlotinib and chemotherapy, respectively. Erlotinib was administered 
orally (p.o.) once a day from Day 2. Docetaxel was administered intravenously (i.v.) 
once in 3 weeks (Day 1). Irinotecan was administered intravenously (i.v.) once in 2 
weeks (Day 1). To evaluate the antitumor effect and tolerability, tumor volume and 
body weight were measured twice a week. The tumor volume (V) was estimated from 
the equation V = ab2/2, where a, and b were tumor length and width, respectively. 
Study 2 
Establishment of in vivo erlotinib PD model and treatment. To establish an in vivo 
erlotinib PD model, a suspension of HPAC cells (5×106 cells/mouse) was inoculated 
subcutaneously into the right flank of the mice. Tumors were allowed to reach 0.1–0.3 
cm3 in size, mice were randomly allocated to control and erlotinib groups. Erlotinib was 
administered orally (p.o.) once a day starting from Day 1 to Day 18. 
After establishment of PD during erlotinib treatment was confirmed, mice were 
re-randomized and allocated to the control group, erlotinib group, gemcitabine group, 
and combination of gemcitabine with erlotinib group and these were treated with 
vehicle of erlotinib and vehicle of gemcitabine, erlotinib and vehicle of gemcitabine, 
vehicle of erlotinib and gemcitabine, or erlotinib and gemcitabine, respectively. 
Erlotinib was administered orally (p.o.) on Days 21–25, 28–32, 35–40. Gemcitabine 
was administered i.v. once a week (on Days 20, 27 and 34). To evaluate the antitumor 
effect and tolerability, tumor volume and body weight were measured twice a week. 
The tumor volume (V) was estimated from the equation V = ab2/2, where a, and b were 
tumor length and width, respectively. 
 
Western blotting 
Cells (HCC827, HCC827TR3, EBC-1 and H1975) were seeded into 6-well plates at 
a concentration of 5×105 cells per well and were preincubated overnight. Then, erlotinib 
was added and incubation continued for 2 h. Cells were stimulated with 100 ng/ml of 
EGF (Invitrogen) for the last 15 min of the incubation. HPAC tumor tissues of the in 
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vivo PD model were pulverized in liquid nitrogen. Cellular total protein was prepared 
from cell lysates and the pulverized frozen tumors. Proteins (100 μg each of HPAC, 
EBC-1 and H1975; 5 μg each of HCC827 and HCC827TR3) were electrophoresed on 
SDS-PAGE with 7.5% gel and transferred onto PVDF membranes (GE Healthcare 
Japan, Tokyo, Japan). The membranes were blocked with a blocking buffer (Thermo 
Fisher Scientific, Kanagawa, Japan), immunoblotted with primary antibody against 
EGFR (Santa Cruz Biotechnology Inc., CA, USA), pY1068 pEGFR (Cell Signaling 
Technology Inc.) and GAPDH (Santa Cruz Biotechnology Inc.). The protein-antibody 
complex was detected by chemiluminescence (GE Healthcare Japan). 
 
Cell proliferation assay 
Cells were seeded at a density of 1000 or 3000 cells/well in 96-well plates and were 
preincubated overnight. The cells were then treated with erlotinib for 96 h. Cell 
proliferation was evaluated by Cell Counting Kit-8 (Dojindo, Kumamoto, Japan). 
 
Statistical analysis 
Statistical analysis to evaluate the antitumor activity was performed using the 
Mann-Whitney U test. For in vitro experiments, Student's t-test was used. Differences 
were considered to be significant at P≤0.05. Statistical analysis was carried out using 
the SAS preclinical package (SAS Institute, Inc., Tokyo, Japan). 
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Results 
Erlotinib sensitivity, EGFR expression and effect of erlotinib on phosphorylation 
of EGFR and downstream signaling molecules in erlotinib-resistant NSCLC cells 
First, I examined the growth inhibition of tumor cells, namely HCC827, 
HCC827TR3, EBC-1 and H1975. HCC827TR3 was 1000 times more resistant to 
erlotinib than parental HCC827 (Fig. 5A) in vitro. I found that the mechanism of 
erlotinib resistance of HCC827TR3 was neither c-Met amplification nor T790M 
mutation in EGFR (data not shown). Almost no growth inhibition was observed in 
EBC-1 and H1975 cells up to 3 μmol/l of erlotinib (Fig. 5B). Next, I examined EGFR 
expression in the tumor cells and the effect of erlotinib on the phosphorylation of EGFR, 
as well as its major downstream signal molecules such as Akt, ERK, Stat3, by Western 
blotting. All of the cell lines expressed EGFR and phosphorylated EGFR (Fig. 5C). The 
EGFR phosphorylation was completely suppressed by erlotinib in HCC827, 
HCC827TR3 and EBC-1, although erlotinib did not inhibit the proliferation of 
HCC827TR3 and EBC-1. On the other hand, erlotinib did not suppress the 
phosphorylation of EGFR in H1975 cells (Fig. 5C). Erlotinib suppressed the 
phosphorylation of Akt and ERK in HCC827 cells. However, out of the three 
erlotinib-resistant cell lines, only a slight inhibition of ERK phosphorylation in 
HCC827TR3 was observed (Fig. 5C). 
 
Antitumor effect of combination therapy of chemotherapeutic agents with erlotinib 
in erlotinib-resistant tumor xenografts 
Because EGFR phosphorylation was suppressed by erlotinib in the erlotinib-resistant 
cells (EBC-1, HCC827TR3), it may be of value to administer erlotinib concurrently 
with a chemotherapeutic agent when treating erlotinib-resistant tumors. Therefore, I 
next examined the antitumor activity of combination therapy of a chemotherapeutic 
agent with erlotinib against these erlotinib-resistant cell lines in xenografts. 
First, I examined the antitumor effect of docetaxel monotherapy and docetaxel + 
erlotinib therapy using the HCC827TR3 xenograft model. In this model, erlotinib 
monotherapy did not show any antitumor effect even at a dose of 25 mg/kg, which was 
higher than the effective dose for parental HCC827 xenograft model (Fig. 6A). 
However, docetaxel in combination with erlotinib showed a significantly higher 
antitumor activity compared with docetaxel monotherapy (Fig. 6B). A similar result was 
obtained in the combination therapy of irinotecan with erlotinib in the same xenograft 
model (Fig. 6C). In the EBC-1 xenograft model, similarly, significantly higher 
22 
 
antitumor effect was obtained in the combination therapy of docetaxel (5 mg/kg) with 
erlotinib (75 mg/kg) compared to docetaxel monotherapy whereas erlotinib did not 
show any antitumor effect at the same dose (Fig. 7). Namely, the combination therapy 
of chemotherapeutic agent with erlotinib showed a significantly higher antitumor effect 
compared with chemotherapy alone while erlotinib monotherapy showed no effect in 
HCC827TR3 or EBC-1 xenografts. On the other hand, no significant effect was seen 
between docetaxel monotherapy (5 mg/kg) and combination of docetaxel (5 mg/kg) 
with erlotinib (75 mg/kg) in the H1975 xenograft model (Fig. 8). 
 
Establishment of in vivo erlotinib-resistant model and antitumor activity of 
gemcitabine in combination with erlotinib 
To mimic the clinical PD phenomenon and examine the effect of combination 
therapy of docetaxel with erlotinib, I established an in vivo erlotinib-resistant model 
using EGFR-positive pancreatic cancer cell line HPAC. The HPAC cells were 
subcutaneously inoculated into BALB/c-nu/nu mice, and erlotinib (75 mg/kg) was 
administered p.o. once a day for 18 days. In this model, erlotinib significantly inhibited 
tumor growth up to 5 days after the start of administration (Fig. 9A). Subsequently, 
however, the tumor growth inhibition effect by erlotinib disappeared, even though 
erlotinib was continuously administered (Fig. 9A). Fig. 9B shows the constant tumor 
volume ratio of erlotinib group to vehicle group after around Day 8. On Day 20, the 
mice in the erlotinib group were randomly allocated to 4 groups, namely, vehicle group, 
erlotinib group, gemcitabine group, and gemcitabine + erlotinib group. Although EGFR 
protein remained positive and its phosphorylation had been substantially reduced by 
erlotinib by Day 21 (Fig. 9C), the erlotinib group did not show significant tumor growth 
inhibition compared with the vehicle group (Fig. 9D). This indicated that the HPAC 
tumors had become resistant to erlotinib. Using this model, I examined the antitumor 
activity of combination therapy of gemcitabine (25 mg/kg) with erlotinib (75 mg/kg). 
The results indicated that the combination therapy showed a significant antitumor effect 
compared with gemcitabine monotherapy (Fig. 9D) even though erlotinib monotherapy 
showed no tumor inhibitory effect. 
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Discussion 
By using two types of tumor models, I was able to investigate the mechanism by 
which NSCLC and pancreatic cancer become resistant to erlotinib. Although EBC-1 
and H1975 show amplification of c-Met and mutation of T790M, respectively, 
HCC827TR3, which was established in-house, has neither. In the HCC827TR3 cells, 
neither EGFR down-regulation nor reduction of EGFR phosphorylation was observed 
(Fig. 5C). The fact that EGFR phosphorylation was inhibited by erlotinib in 
HCC827TR3 cells but the PI3K pathway was not inhibited and the Ras-ERK/MAPK 
pathway only partially inhibited (Fig. 5C) indicates that the resistance mechanism may 
be the activation of these pathways by protein kinase(s) other than c-MET. (Fig. 10) 
Erlotinib completely inhibited EGFR phosphorylation in EBC-1 and HCC827TR3 
cells but not in H1975 cells (Fig. 5C). This coincides well with the previous reports (14, 
69, 70) which state that, in cells with c-Met amplification, erlotinib resistance is 
activated in the cell growth signaling pathway through heterodimer formation of MET 
and HER3 molecules. Thus, EGFR remains intact in c-Met amplification cells such as 
EBC-1, and erlotinib is able to inhibit EGFR phosphorylation. In the case of 
HCC827TR3, although the precise mechanism of resistance is not yet clear, it would 
seem that EGFR phosphorylation was inhibited by a similar mechanism. On the other 
hand, erlotinib could not inhibit EGFR phosphorylation in H1975 cells because the 
T790M mutation in EGFR causes a conformation change at the ATP binding pocket, 
thus decreasing the affinity between erlotinib and EGFR. 
Since all of the erlotinib-resistant cell lines express EGFR, I examined the antitumor 
effect of combination therapy of erlotinib with docetaxel or irinotecan. In these models, 
erlotinib monotherapy did not show significant antitumor effect compared with the 
control group (Figs. 6A, 7 and 8). Interestingly, however, combination therapy of 
docetaxel with erlotinib showed a synergistic effect in HCC827TR3 (Fig. 6B) and 
EBC-1 (Fig. 7) xenografts. A similar result was obtained in HCC827TR3 xenografts 
using irinotecan as a chemotherapeutic agent (Fig. 6C). These results may indicate that 
the chemotherapeutic agent used in the combination therapy need not be restricted to a 
specific drug. On the other hand, no significant increase of antitumor effect of 
combination therapy compared with docetaxel monotherapy was observed in H1975 
xenografts (Fig. 8). These results coincide well with the report of Okabe et al in which 
gefitinib and S-1 were used in combination in H1975 and HCC827GR5 xenografts (72). 
Since EGFR phosphorylation was completely inhibited by erlotinib in HCC827TR3 
cells and EBC-1 cells but not in H1975 cells (Fig. 5C), it is possible that inhibition of 
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EGFR phosphorylation is prerequisite for the combination therapy to be effective. 
EGFR phosphorylation activates signal transduction pathways, such as PI3K and 
Ras-ERK/MAPK, and erlotinib inhibits these pathways. However, the role of erlotinib 
in combination therapy in erlotinib-resistant xenograft models may be inhibition of 
signal pathway(s) other than the PI3K or Ras-ERK/MAPK pathways, because erlotinib 
monotherapy did not show any antitumor effect in HCC827TR3 and EBC-1 xenografts. 
In the H1975 xenograft model, erlotinib failed to inhibit EGFR phosphorylation (Fig. 
5C) hence the antitumor effect of combination therapy was not enhanced. Okabe et al 
reported that the combination effect of S-1 with gefitinib was attributed to the 
down-regulation of thymidylate synthase (TS) by gefitinib and the mechanism could 
work even after the tumor cells became resistant to gefitinib (72). I consider that similar 
mechanisms are involved in my system, although the target molecules have so far not 
been specified. In the case of EBC-1, combination therapy using docetaxel was 
expected to reduce c-MET in cells, but this was not observed (data not shown). It was 
reported that erlotinib restores the effect of chemotherapeutic agents through direct 
inhibition of PgP or BCRP (73, 74). However, this is unlikely because verapamil, a PgP 
or BCRP inhibitor, did not restore the sensitivity to docetaxel in HCC827TR3 cells 
(data not shown). 
In my HPAC in vivo model which mimics PD in clinical therapy, the combination 
therapy of gemcitabine with erlotinib showed significantly strong antitumor effect 
compared with gemcitabine monotherapy (Fig. 9D). EGFR expression and 
phosphorylated EGFR were detected in the tumors of the control group after PD had 
developed. Surprisingly, phosphorylation of EGFR was completely inhibited in the 
tumors of the erlotinib group (Fig. 9C). These results indicate the usefulness of the 
combination therapy of a chemotherapeutic agent with erlotinib against in vivo-induced 
erlotinib-resistant tumors. 
Erlotinib is currently approved for the treatment of NSCLC and pancreatic cancer. In 
the present study, I showed that combination therapy of a chemotherapeutic agent with 
erlotinib is efficacious against two erlotinib-resistant NSCLC cell lines (EBC-1, 
HCCC827TR3) and one pancreatic cancer cell line (HPAC) which had become erlotinib 
resistant, suggesting that this form of treatment would be useful against NSCLC and 
pancreatic cancer which developed PD. Erlotinib has been reported to have an excellent 
benefit for patients with NSCLC harboring mtEGFR and to prolong the overall survival 
of patients with NSCLC harboring wtEGFR (11). The combination therapy may be 
effective regardless of the EGFR mutation status because it was effective on both 
HCC827TR3 (mtEGFR) and HPAC (wtEGFR) cells. 
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The results suggest that combination therapy of a chemotherapeutic agent with 
erlotinib showed stronger antitumor effect compared with chemotherapy alone against 
erlotinib-resistant tumors in that erlotinib inhibited the phosphorylation of EGFR in the 
tumor. It may be possible to obtain evidence for the suitability of the combination 
therapy by monitoring the EGFR phosphorylation level in tumors after PD has 
developed following erlotinib treatment. However, this test cannot distinguish tumors 
which had intrinsically low EGFR phosphorylation and, to solve the problem, it may be 
necessary to test the EGFR phosphorylation level before the start of erlotinib therapy. In 
the present study, docetaxel, irinotecan and gemcitabine were used as chemotherapeutic 
agents. Whether or not similar results can be obtained with other chemotherapeutic 
agents is an issue for future research. If a patient goes into PD during combination 
therapy, a possible treatment modality may be to change the chemotherapeutic agent 
while continuing erlotinib. 
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General Discussion 
In cancer treatment, chemotherapy have been used for a long time. However, they 
cause severe side-effects because their activity is not specific to tumors. The specific 
action of targeted therapy, which stops the action of molecules that are key to the 
growth of cancer cells, differs from traditional chemotherapy, which affects all 
fast-growing cells. Therefore many targeted agents have been developed recently to 
limit toxicity and to improve the efficacy of cancer therapy. 
There are two main types of targeted therapy. The first type targets tumor cells by 
attacking molecules expressed on the surface or activated in the cytoplasm of cancer 
cells (1-3). The second type targets the tumor microenvironment by attacking tumor 
angiogenesis and the antitumor immune response. It has long been recognized that 
construction of blood vessels in the tumors is necessary to supply sufficient nutrition 
and oxygen for tumor cells to proliferate. VEGF is an important factor in tumor 
angiogenesis and growth (22-25), but VEGF-independent angiogenesis has been 
reported as a mechanism of resistance to anti-VEGF therapy (48). In order to establish a 
colorectal cancer xenograft model that develops resistance to anti-VEGF antibody, five 
human colorectal cancer xenografts were treated with anti-VEGF antibody. Although at 
first anti-VEGF antibody exhibited significant antitumor activity in all of the five 
models, in the HT-29 model anti-VEGF antibody exhibited significant antitumor 
activity in the early phase but not in the late phase, indicating that the HT-29 model 
became non-sensitive to anti-VEGF antibody during treatment. Also, no difference was 
observed in the tumor vessel density of HT-29 tumor tissue from the control and 
bevacizumab groups. These facts indicate that HT-29 tumor has VEGF-independent 
angiogenesis. However, even in the presence of VEGF-independent angiogenesis, 
HT-29 continues to express VEGF.  
It was previously reported that the molecular targeted drug trastuzumab exhibited 
antitumor effects when administered with chemotherapeutic agents after the tumor had 
acquired resistance to monotherapy, if the tumor kept expressing the target molecule 
(53). Similarly, when a tumor continues to express VEGF, combining an anti-VEGF 
antibody with second-line chemotherapy after resistance has been acquired, may be an 
appropriate therapy. Therefore, I hypothesized that BBP therapy is effective even after a 
tumor acquires resistance to anti-VEGF antibody, and I used the HT-29 PD model to 
investigate the antitumor effect of the combination of an anti-VEGF antibody plus 
capecitabine. Of note, the combination of anti-VEGF antibody plus capecitabine 
exhibited a significantly stronger antitumor effect than capecitabine alone. These data 
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suggested that it is important to continue to inhibit VEGF by an anti-VEGF antibody in 
combination with an appropriate chemotherapeutic agent, even after the tumor has 
acquired resistance to the anti-VEGF antibody per se. Next, I used the same model to 
investigate the mechanism by which the combination of anti-VEGF antibody plus 
capecitabine achieved this antitumor effect. The results showed that tumor vessel 
density was significantly reduced in the combination group, whereas it was not reduced 
in the groups receiving anti-VEGF antibody or capecitabine alone at this stage. In 
addition, the level of galectin-3, which is known as an important mediator of angiogenic 
response, was significantly decreased in the capecitabine and combination groups 
compared with the control group. In contrast to galectin-3 levels, VEGF levels increased 
in the capecitabine treatment group in our model, and this bilateral effect of 
capecitabine on the production of angiogenic factors may be a reason for the apparent 
absence of anti-angiogenic effect by capecitabine alone. Nevertheless, by neutralization 
of VEGF through concurrent administration of bevacizumab, a synergistic 
anti-angiogenic effect emerged. These data raise the possibility that the inhibition of 
galectin-3 production by capecitabine and the neutralization of VEGF by bevacizumab 
formed the mechanisms underlying the effect of combination treatment. 
EGFR genetically overexpressed on the surface of cancer cells, and EGFR is the 
major contributors of a complex signaling cascade that modulates growth and survival 
of cancer cells. EGFR-TKI reversibly binds to the intracellular domain of EGFR. This 
blocks autophosphorylation of EGFR with subsequent inhibition of the downstream 
signaling pathways which promote cell proliferation. Two mechanisms of acquired 
resistance to EGFR-TKI, i) resistant EGFR mutations, and ii) activation of bypass 
pathways or downstream pathways, have been suggested in the literature. 
To analyze the characteristics of EGFR-TKI-resistant tumor, I used models with 
EGFR-TKI-resistant tumors which continue to express EGFR. Because EGFR 
phosphorylation was completely inhibited by EGFR-TKI in HCC827TR3 cells, EBC-1 
cells, and HPAC in vivo resistant-tumor, but not in H1975 cells, it is possible that 
inhibition of EGFR phosphorylation is prerequisite for the combination therapy to be 
effective. Therefore, I examined the antitumor effect of combining chemotherapy with 
EGFR-TKI. In these models, EGFR-TKI monotherapy did not show significant 
antitumor effect compared with the control group, but interestingly, combination 
therapy of chemotherapeutic agent showed a synergistic effect in the HCC827TR3 and 
EBC-1 models. These results may indicate that the chemotherapeutic agent used in the 
combination therapy need not be restricted to a specific drug. On the other hand, no 
significant increase in the antitumor effect of combination therapy compared with 
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chemotherapeutic agent monotherapy was observed in the H1975 model. Although an 
EGFR-TKI inhibits the signal transduction pathways activated by EGFR 
phosphorylation, such as PI3K and Ras-ERK/MAPK, the role of EGFR-TKI in 
combination therapy in EGFR-TKI-resistant tumor may be to inhibit signal pathway(s) 
other than the PI3K or Ras-ERK/MAPK pathways, because EGFR-TKI monotherapy 
did not show any antitumor effect in the HCC827TR3 and EBC-1 models. It may be 
possible to obtain evidence for the suitability of the combination therapy by monitoring 
the EGFR phosphorylation level in tumors after PD has developed following 
EGFR-TKI treatment. 
In these studies, I showed that tumors continue to express the target molecule after 
acquiring resistance to therapy, and combining VEGF- or EGFR-targeted therapy with 
chemotherapy exerted strong antitumor activity, even after resistance to the targeted 
therapy was acquired, by inhibiting the effect of the target molecules. These results 
indicate that VEGF- or EGFR-independent tumor depended on these molecules again 
through chemotherapy treatment. Tumor cell may have instability not only in drug 
sensitivity but also in drug resistance. And chemotherapy may enhance the instability in 
drug resistance and reverse the resistance. 
It has been reported that after resistance has been acquired to other targeted drugs, 
tumors continue to express the target molecule (75, 76). Therefore, targeted therapy in a 
combination with chemotherapy after PD may be applicable in many other targeted 
therapies. 
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Table 1. 
VEGF expression levels in tumor tissue of colorectal cancer xenograft models. 
Tumor type VEGF (pg per mg protein) 
HCT-8 1669 
COLO 205 1778 
HCT 116 2539 
HT-29 3132 
LS411N 3540 
39 
 
 
 
 
Figures 
40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 
Bevacizumab shows antitumor activity in the early phase but not in the late phase in 
HT-29 xenograft model. Mice were randomized into 2 groups (n=5–10/group). 
Bevacizumab and control human IgG were intraperitoneally administered once a week. 
Data points show mean ± SD of tumor volume. Control, open circles; bevacizumab, 
closed circles. a: P<0.05 versus control IgG group by Wilcoxon test. 
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Figure 2.  
Combination therapy with bevacizumab plus capecitabine inhibits tumor growth and 
tumor angiogenesis in the HT-29 xenograft bevacizumab PD model. Antitumor activity 
(A) and anti-angiogenic activity (B) of combination therapy with capecitabine plus 
bevacizumab in the HT-29 xenograft model unresponsive to bevacizumab. Mice that 
had been treated with bevacizumab on days 1 and 8 were randomly allocated to control, 
bevacizumab, capecitabine, and bevacizumab plus capecitabine groups on day 29 
(n=7/group). CD31 immunostaining in tumor tissue at day 50 (n=7/group). Data points 
show mean ± SD of tumor volume. Control, open circles; bevacizumab, closed circles; 
capecitabine, cross marks; combination group, closed triangles. The box-and-whisker 
plots show mean ± SD. a: P<0.05 versus control group; b: P<0.05 versus capecitabine 
group; c: P<0.05 versus bevacizumab group by Wilcoxon test. 
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Figure 3.  
Combination therapy did not change the expression of stromal cell-derived angiogenic 
factors in tumor tissues. Changes in stromal cell-derived angiogenic factors. 
Membranes-based antibody arrays were reacted with homogenized tumor tissue 
harvested from the control, bevacizumab, capecitabine, and combination group on day 
50. 
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Figure 4.  
Combination therapy suppresses tumor cell-derived VEGF and galectin-3 in tumor 
tissues. (A) Membranes-based antibody arrays were reacted with tumor tissue 
homogenates from the control group, bevacizumab group, capecitabine group, and 
combination group on day 50. (B) Levels of free VEGF in the tumor tissues (n=7). (C) 
Levels of galectin-1 and galectin-3 in the tumor tissues (n=7). The control group (open), 
bevacizumab group (horizontal striped), capecitabine group (hatched), and combination 
group (closed). Columns show mean ± SD. a: P<0.05 versus control by Wilcoxon test. 
(D) Downregulation of galectin-3 expression by 5-FU in in vitro culture. Culture 
supernatant was collected and subjected to ELISA (n=3). Columns show mean ± SD. a: 
P<0.05 versus control by Dunnett's test.
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Figure 5.  
Erlotinib sensitivity, EGFR expression and effect of erlotinib on phosphorylation of 
EGFR and downstream signaling molecules in cancer cell lines in vitro. (A) Growth 
inhibition of erlotinib in parental HCC827 (●) and resistant HCC827TR3 (□). (B) 
Growth inhibition by erlotinib in EBC-1 (○) and H1975 (□). (C) Expression of EGFR 
and inhibition of phosphorylation in signal transduction molecules by erlotinib in 
NSCLC cell lines.
A B 
C 
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Figure 6. 
Antitumor effect in parental HCC827 and resistant HCC827TR3 xenograft models. (A) 
Erlotinib monotherapy at Day 22. □, control; ■, erlotinib 15 mg/kg (HCC827), 25 
mg/kg (HCC827TR3), n=5/group. (B) Combination therapy of docetaxel with erlotinib 
in HCC827TR3 xenograft model. □, control; ○, erlotinib 25 mg/kg; △, docetaxel 20 
mg/kg; ● , combination, n=7/group. (C) Combination therapy of irinotecan with 
erlotinib in HCC827TR3 xenograft model. □, control; ○, erlotinib 25 mg/kg; △, 
irinotecan 60 mg/kg; ●, combination, n=5/group. Statistically significant differences 
are shown. NS, not significant; *P≤0.05, **P≤0.01, ***P≤0.001 by Wilcoxon test.
A B C 
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Figure 7. 
Antitumor effect of docetaxel in combination with erlotinib in EBC-1 xenograft model. 
□ , control; ○ , erlotinib 75 mg/kg; △ , docetaxel 5 mg/kg; ● , combination, 
n=6/group. Statistically significant differences are shown. NS, not significant; **P≤0.01 
by Wilcoxon test. 
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Figure 8. 
Antitumor effect of docetaxel in combination with erlotinib in H1975 xenograft model. 
□ , control; ○ , erlotinib 75 mg/kg; △ , docetaxel 5 mg/kg; ● , combination, 
n=7/group. Statistically significant differences are shown. NS, not significant.
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Figure 9. 
Establishment of an in vivo erlotinib-resistant model and antitumor activity of 
gemcitabine in combination with erlotinib. (A) Ratio between tumor volume and that of 
4 days previously. Appearance of the progressive tumor during 19 days of treatment 
with erlotinib is shown. Mice were allocated to groups of 6 mice for control and 70 
mice for erlotinib treatment. Erlotinib was administered p.o. qd for 19 days. ●, control; 
×, erlotinib 75 mg/kg. (B) Time course of the tumor volume ratio of erlotinib group to 
vehicle group. (C) Expression and phosphorylation of EGFR after acquiring resistance. 
Tumor tissues after acquiring resistance to erlotinib treatment were collected on Day 21. 
(D) Antitumor activity of gemcitabine in combination with erlotinib. On Day 20 of 
erlotinib treatment, mice in the erlotinib group were randomly allocated to 4 groups 
(n=6/group). □, control; ○, erlotinib 75 mg/kg; △, gemcitabine 25 mg/kg; ●, 
combination. Statistically significant differences are shown. NS, not significant. 
***P≤0.001, *P≤0.05 by Wilcoxon test. 
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Figure 10. 
Mechanisms of EGFR resistance to EGFR-TKI. (A) EGFR-TKI inhibits 
phosphorylation of EGFR and leads to apoptosis of cells. (B) T790M mutation prevents 
binding of EGFR-TKI to EGFR, resulting in cell survival. (C) Amplification of MET 
activates the downstream signaling pathways. (D) Activating mutation of the 
downstream signaling pathways leads to survival of cells. 
 
